1. Home
  2. HOWL vs GNLX Comparison

HOWL vs GNLX Comparison

Compare HOWL & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Werewolf Therapeutics Inc.

HOWL

Werewolf Therapeutics Inc.

HOLD

Current Price

$0.96

Market Cap

48.1M

Sector

Health Care

ML Signal

HOLD

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.60

Market Cap

123.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOWL
GNLX
Founded
2017
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.1M
123.1M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
HOWL
GNLX
Price
$0.96
$2.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$5.00
$17.25
AVG Volume (30 Days)
10.4M
360.7K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
18.40
9.47
EPS
N/A
N/A
Revenue
N/A
$8,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$2.29
52 Week High
$2.23
$8.54

Technical Indicators

Market Signals
Indicator
HOWL
GNLX
Relative Strength Index (RSI) 82.17 43.74
Support Level $0.80 $2.33
Resistance Level $1.17 $2.98
Average True Range (ATR) 0.07 0.17
MACD 0.04 -0.00
Stochastic Oscillator 89.45 17.23

Price Performance

Historical Comparison
HOWL
GNLX

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Share on Social Networks: